Abstract
Acyl-CoA binding protein (ACBP) encoded by diazepam binding inhibitor (DBI) is an extracellular inhibitor of autophagy acting on the gamma-aminobutyric acid A receptor (GABAAR) γ2 subunit (GABAARγ2). Here, we show that lipoanabolic diets cause an upregulation of GABAARγ2 protein in liver hepatocytes but not in other major organs. ACBP/DBI inhibition by systemically injected antibodies has been demonstrated to mediate anorexigenic and organ-protective, autophagy-dependent effects. Here, we set out to develop a new strategy for developing ACBP/DBI antagonists. For this, we built a molecular model of the interaction of ACBP/DBI with peptides derived from GABAARγ2. We then validated the interaction between recombinant and native ACBP/DBI protein and a GABAARγ2-derived eicosapeptide (but not its F77I mutant) by pull down experiments or surface plasmon resonance. The GABAARγ2-derived eicosapeptide inhibited the metabolic activation of hepatocytes by recombinant ACBP/DBI protein in vitro. Moreover, the GABAARγ2-derived eicosapeptide (but not its F77I-mutated control) blocked appetite stimulation by recombinant ACBP/DBI in vivo, induced autophagy in the liver, and protected mice against the hepatotoxin concanavalin A. We conclude that peptidomimetics disrupting the interaction between ACBP/DBI and GABAARγ2 might be used as ACBP/DBI antagonists. This strategy might lead to the future development of clinically relevant small molecules of the ACBP/DBI system.
Similar content being viewed by others
Introduction
Human acyl-coenzyme A binding protein (ACBP) is encoded by diazepam binding inhibitor (DBI) gene. This double name, ACBP/DBI, reflects the dual function of this small (~10 kDa) protein, which binds to medium- and long- chain acyl coenzyme A (CoA) esters within cells, but can also be secreted into the extracellular space. ACBP/DBI acts on diazepam receptors on the surface of cells in an auto-, para- or endocrine fashion [1,2,3]. It is phylogenetically conserved and appears to act as an extracellular inhibitor of autophagy, meaning that its neutralization enhances autophagy in yeast [4], plants [5, 6], nematodes [7], mice [8, 9] and human cell cultures [8].
ACBP/DBI expression is upregulated in metabolic human diseases including obesity [8, 10], diabetes [11] and non-alcoholic steatohepatitis [12]. Mouse experimentation has shown that the neutralization of ACBP/DBI has positive effects on metabolism, reducing appetite and blunting high-fat diet-induced obesity and diabetes [8]. ACBP/DBI inhibition also prevents liver damage from various insults including mechanical damage (ischemia/reperfusion, bile duct ligation), dietary stress (high-fat, Western-style or methionine/choline-deficient diet) and hepatotoxins (acetaminophen, carbon tetrachloride, concanavalin A) [9].
These metabolic and hepatoprotective effects have been obtained through two different strategies of ACBP/DBI inhibition. At the genetic level, ACBP/DBI can be safely knocked out in adult mice using a tamoxifen-inducible Cre recombinase that excises the floxed Acbp/Dbi exon 2 in all cells of the body [8]. Alternatively, Gabrg2 can be safely mutated in one single amino acid (F77I) at a constitutive level to abolish its interaction with its ligand ACBP/DBI [13, 14]. At the immunological level, ACBP/DBI autoantibody productions can be induced by a specific autovaccination schedule that breaks self-tolerance, leading to the generation of neutralizing IgG anti-ACBP/DBI antibodies [15]. Alternatively, ACBP/DBI can be neutralized by the systemic (intraperitoneal) injection of specific poly- or monoclonal antibodies [13]. The fact that antibodies and receptor mutations are as efficient in neutralizing pathogenic functions of ACBP/DBI, as the knockout of Acbp/Dbi [9], supports the importance of extracellular (as opposed to intracellular) ACBP/DBI in mediating obesogenic, pro-diabetic and hepatotoxic effects. Indeed, a mutated ACBP/DBI protein that loses its capacity to interact with acyl-CoA (and thus the intracellular function of the protein) is as efficient as the unmutated ACBP/DBI in inducing appetite in mice [16].
Driven by this, we wondered whether it might be possible to design peptides that inhibit extracellular ACBP/DBI and hence act as ACBP/DBI antagonists. Logically, we considered the possibility of designing such peptides from the ACBP/DBI receptor GABAAR. Here, we employed this strategy to design a peptide that flanks F77 from GABAARγ2 and interacts with recombinant or natural ACBP/DBI to block the metabolic effects of ACBP/DBI in vitro (on primary hepatocytes) and in vivo (in mice), specifically in terms of appetite control and hepatotoxicity. These findings have important consequences for the future design of small molecules affecting the ACBP/DBI-GABAAR interaction.
Materials and methods
Mouse experiments
All mice used in this study were bred and housed in a pathogen-free, temperature-controlled environment with 12 h light/dark cycles following the FELASA guidelines, EU Directive 63/2010, and French legislation. C57BL/6 8–12-week-old male mice were acquired from Envigo (Envigo, Gannat, France) or Charles River (Charles River Laboratory, Lentilly, France). Tamoxifen-inducible whole-body knockout of floxed Acbp/Dbif/f (ACBP KO: UBC-cre/ERT2::Acbp/Dbifl/fl; ACBP WT control: Acbp/Dbifl/fl without Cre [8] were bred in the CRC animal facility. Mice were housed in SPF conditions with a 12 h light/dark cycles, temperature-controlled environment and received water and food ad libitum. Mice received a regular chow (RCD, Safe, #A04), 60% high-fat (Safe, #260 HF), high-fat/high-sucrose/1.25% cholesterol Western (WD) (Teklad, #MD.120528), or methionine/choline-deficient (MCD) (Essingen, #AIN-76) diet. In one series of experiments, C57BL/6 transgenic mice expressing microtubule-associated proteins 1A/1B light chain 3B (hereafter referred to as LC3) fused to green fluorescent protein (GFP) [17] were kindly provided by Noboru Mizushima (National Institute for Basic Biology, Okazaki, Japan). Mice were randomized into experimental groups, though without blinding the investigators.
Food intake experiments
Prior to experimentation, mice were subjected to 24 h starvation followed by individual housing and acclimatization in individual cages (2 h). Subsequently, mice were intravenously (i.v.) injected with recombinant ACBP/DBI protein (RecACBP/DBI) (total volume of 200 μL, 0.5 mg/kg body weight), either alone or in combination with GABAARγ2 peptides (5× molar excess). Cumulative food intake was then analyzed as previously described [16]. Prior to i.v. injections, the RecACBP mixes were pre-incubated (16 h, 4 °C) with GABAARγ2 peptides.
Liver autophagy activation by GABAARγ2 peptides
Ten-week-old C57BL/6 male mice were injected with GABAARγ2 peptides (5 mg/kg, i.v., dissolved in PBS) 4 h and 30 min before sacrifice. For inhibition of the autophagy flux, leupeptin (Leu, 30 mg/kg B.W., dissolved in PBS) was injected 2 h before sacrifice via an intraperitoneal (i.p.) injection. Control animals were i.v. injected with the vehicle (DMSO, 0.01%) and i.p. injected with PBS. All animals were sacrificed, and livers were snap-frozen in liquid nitrogen and stored at −80 °C.
Concanavalin A-induced acute liver injury
GABAARγ2 peptides (5 mg/kg, i.v., dissolved in DMSO) were injected in 12-week-old C57BL/6 male mice 90 min before the injection of 12 mg/kg Concanavalin A (ConA, i.v., Sigma Aldrich, # C5275) [9].
Primary mouse hepatocyte isolation and culture
Hepatocytes were isolated from control Acbp/Dbi f/f, Acbp/Dbi KO and GFP-LC3-expressing transgenic mice by perfusion through the inferior vena cava with Hank’s Balanced Salt Solution (HBSS 1×) (Gibco, # 14025092), 1 mM HEPES (pH = 7.4), 0.2 mM EGTA, and William’s E medium (Sigma) containing 7.5 mg collagenase from Clostridium histolyticum (Type IV, 0.5–5.0 FALGPA units/mg solid, ≥125 CDU/mg solid, Sigma). After filtration through a 100 µm cell strainer and successive centrifugations at 30 × g, 4 °C for 5 min, cells were resuspended in the following attachment culture medium: DMEM/F12, 20 mM HEPES (pH = 7.4), 5 mM glucose, 10% FBS (Sigma), 5 mg/mL BSA, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were then purified by density gradient centrifugation using an isotonic solution of Percoll (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Cell viability was assessed using Trypan blue exclusion. Cells were plated in a 96-well plate overnight to facilitate cell attachment before proceeding with experiments [18].
Hepatocyte autophagy activation by GABAARγ2 peptides
GFP-LC3-expressing hepatocytes were cultured at 37 °C in complete medium supplemented with either vehicle or GABAARγ2-derived peptides (10 µg/mL) for 18 h. Leupeptin (100 μM) was added 4 h before fixation. Cells were stained with Hoechst 33342 solution (Thermo Scientific™, #62249, 1 µg/mL) and fixed with 4% paraformaldehyde (PFA) solution. Both blue (Hoechst-derived) and green (GFP-LC3-derived) fluorescence were imaged using a Zeiss LSM 710 confocal microscope. Images were analyzed using R software.
Liver histology
Mouse liver samples were fixed in 20–30 mL 4% v/v formaldehyde solution (4 °C) for 24–48 h, followed by dehydration (incubation in gradually increasing ethanol solutions; 70–100% v/v) and paraffin inclusion as previously described [14]. Five-micrometer sections were stained using hematoxylin and eosin (HE), or immunohistochemically using anti-mouse GABRG2 (Antibodies online #AA41–140) according to standard procedures. Sections were then scanned by means of a Zeiss Lame Axioscan (objective: ×20). Images were analyzed using Image J or Zen software.
Immunofluorescence in liver sections
Analysis of murine GABAARγ2 levels was performed in livers via immunofluorescence. Livers were fixed in 20–30 mL 4% v/v formaldehyde solution (4 °C) for 24 h, followed by 30% sucrose treatment (4 °C) overnight. Samples were embedded in Tissue-Tek OCT compound (Sakura Finetechnical) and stored at −80 °C as previously described [9]. Five-micrometer-thick tissue sections were prepared with a cryostat (Leica Microsystems, #CM3050S), air-dried for 30 min, and washed three times in PBS for 5 min. Sections were then permeabilized (0.2% Triton X-100) for 10 min, washed three times in PBS for 5 min, and blocked (0.1% Triton X-100, 10% horse serum, 1% BSA, room temperature) for 2 h. Samples were finally incubated overnight in the primary antibody mix (Mouse Gabrg2: Abcam #ab87328, Mouse F4/80: MCA497G, Mouse Albumin: R&D Systems #AF3329). After washed in PBS, samples were incubated in secondary antibody mix (Anti-rabbit AF647 1:500, Anti-goat AF488 1:500) at room temperature for 1 h and mounted with DAPI Fluoromount-G® antifading medium (SouthernBiotech, AL, USA). The slides were scanned using a LSM 710 confocal fluorescence microscope (Carl Zeiss, Jena, Germany). Hepatic GABAARγ2 levels were quantified across all sections of liver tissue samples visualized in fields of view from four mice per group, utilizing R Software.
Chemicals, cell lines, culture conditions
Media and cell culture supplements were purchased from Gibco-Invitrogen (Carlsbad, CA, USA). Plasticware was purchased from Corning B.V. Life Sciences (Schiphol-Rijk, The Netherlands). Unless reported otherwise, the cell line used in this study was cultured at standard conditions (37 °C, 5% CO2, Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, 10 mM HEPES buffer, 100 mg/L sodium pyruvate, 100 U/mL penicillin G sodium, and 100 µg/mL streptomycin sulfate). 2-deoxy-D-glucose (# D8375) and rotenone (# R8875) were purchased from Sigma (Burlington, MA, USA). Human hepatocellular carcinoma (Huh-7) cell line was used for in vitro experiments. Cells were plated in 6- or 96-well plates and grown for 24 h before treatments.
Stable shAcbp-expressing Huh-7 cell line
shRNAs directed against Acyl-CoA Binding Protein (Acbp), shAcbp-3 (TRCN0000105050), as well as a negative control shRNA, were inserted into the pLKO.1-puro lentiviral vector obtained from Sigma (Burlington, MA, USA). Approximately 2 × 105 Huh-7 cells were seeded in a six-well plate with Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) until reaching 60–70% confluence. Subsequently, the cells were transduced with lenti-shRNA particles (25–35 μL) in 1 mL fresh medium (DMEM, 10% FBS, 5 μg/mL Polybrene, Sigma, Burlington, MA, USA, # TR-1003). Following transduction, the medium was replaced 24 to 48 h later (DMEM, 10% FBS), and cells were incubated for an additional day. Puromycin selection (10 µg/mL, Thermo Fisher Scientific, Carlsbad, CA, USA, #A1113803) was applied for 1 week to isolate the successfully transduced Huh-7 cells. For the isolation of monoclonal stable cell lines, single-cell sorting was conducted following standard protocols.
WST-8 conversion
WST-8 conversion assays were conducted utilizing the Cell Counting Kit-8 (Sigma-Aldrich, #96992). Cells were seeded in a 96-well plate at a density of 3000 cells per well and incubated overnight for adherence. Then, the culture medium was removed, and fresh medium containing the specified treatments was added to the wells. Immediately following the addition of treatments, 10 μL of CCK-8 reagent was introduced to each well. Subsequently, the cells were incubated for 4.5 h at 37 °C to facilitate the conversion of WST-8 in response to cellular activity. Following the incubation period, the absorbance at 450 nm was quantified using a VICTOR® Nivo™ microplate reader. This measurement served as an indicator of WST-8 conversion, reflecting cellular metabolic activity.
Immunoblot
Protein lysates were prepared from liver, epididymal white adipose tissue (eWAT), brown adipose tissue (BAT), muscle, heart or Hep55.1c cells. Immunoblot analysis was performed for GABAARγ2 (Abcam #ab87328), mouse ACBP/DBI (Abcam, #ab231910), Human ACBP (Santa-Cruz #sc-376853), MAP1LC3B (#2775, Cell Signaling Technologies), and β-actin (Abcam, #ab49900), as previously described. [14].
Pull down experimentation assay
The physical interaction between the native ACBP and GABAARγ2 peptides was examined by standard immunoprecipitation (IP) and immunoblotting protocols. In detail, liver protein extracts (500 μg) were immunoprecipitated on protein A/G-Sepharose beads (Merck Millipore, Burlington, MA, USA, #GE17-0618-01) coated with (1× 2× 4×) either GABAARγ2 wild type (WT) or mutated (F77I) eicosapeptide (Biosynth ltd) or its negative control (PBS). Each IP reaction was incubated overnight (4 °C) in a rotation chamber followed by three consecutive rounds of PBS washing the next day. Each washing round included a PBS resuspension of the pellet and a re-centrifugation (12,000 × g, 4 °C). Finally, beads were resuspended in 20 μL of NUPAGE 4× buffer (Life Technologies, CA, USA, #NP0008), heated at 100 °C (10 min), followed by standard immunoblotting for the ACBP protein (Abcam #ab231910).
Computational protein modeling
Peptide-protein docking structure between mouse ACBP/DBI and GABAARγ2-derived eicosapeptide was previously described [19]. To that end, an artificial sequence was created concatenating ACBP/DBI protein sequence with GABAARγ2-derived eicosapeptide, separated by a linker of 30 glycine residues (N-ACBP/DBI-(Gly)30-GABAARγ2 peptide). Then, Alphafold (v.2.3.1) was used to predict the resulting molecular structure. The program was run in monomer mode, using all the databases, and modifying the number of recycles from three to nine. The protein structures generated were then analyzed using UCSF ChimeraX visualization software [20]. In order to elucidate the interacting residues in ACBP/DBI- GABAARγ2 eicosapeptide structure, the H-bonds tool from ChimeraX was run with default settings and the most frequent predicted interactions were annotated.
Real time interaction analyses
Kinetics of interaction of recombinant murine ACBP/DBI (Institute of Psychiatry and Neuroscience of Paris, France) with GABAARγ2 -derived eicosapeptide or its mutated derivative (synthesized by Biosynth ltd) was analyzed by surface plasmon resonance-based biosensor system – Biacore 2000 (Cytiva Life Sciences, Biacore, Uppsala, Sweden). SA sensor chip (Cytiva Life Sciences, Biacore) was activated by three consequent injections of 1 M NaCl, 0.05 M NaOH solution. After washing the sensor chip surface, biotinylated ACBP/DBI was immobilized on it. ACBP was diluted in HBS-EP buffer (10 mM HEPES pH 7.2, 150 mM NaCl, 3 mM EDTA, and 0.005% Tween-20) at final concentration of 10 µg/mL and injected for 5 min contact time. The achieved immobilization density of ACBP was 1600 resonance units.
All analyses were performed in HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20; 0.22 µm filtered and degassed). The system was run at flow rate of 30 μL/min. The temperature on chip surface was set to 25 °C. GABAARγ2-derived eicosapeptide or its mutated derivative (both stocked in DMSO at 1 mg/mL) were diluted in HBS-EP to 10 µM and 100 µM. The peptides were injected over immobilized ACBP/DBI and a control surface (streptavidin alone). The association and dissociation phases of the interaction were followed for 4 and 5 min, respectively. The interaction of peptides with ACBP/DBI was assessed by monitoring the dissociation from the immobilized protein. For visualization of the binding response Graph Pad Prism software was used.
Statistics
The in vivo experiments were performed with 3–9 animals per group. Data were reported as columns or box plots (with each dot representing one biological replicate) including the mean ± SEM. The sample size is noted in the figures. Normality tests and equal variance tests (F or Bartlett) were performed. Statistical significance was analyzed using Mann–Whitney test, unpaired two-tailed Student’s t-test, or one-way ANOVA. Differences were considered statistically significant when p values were p < 0.05 or non-significant (ns) when p > 0.05.
Results
GABAARγ2 upregulation by obesogenic diets
C57BL/6 mice were fed with obesogenic diets, either high-fat diet (HFD) or Western style high-fat/sucrose/cholesterol diet (WD) for 6 weeks (Fig. 1A), which yielded similar weight gain (Fig. 1B), correlating with an elevation of plasma ACBP/DBI concentrations (Fig. 1C), in agreement with previous findings [8, 14, 21]. We performed immunoblot analyses using a GABAARγ2-specific antibody (Fig. S1) in order to determine the levels of the ACBP/DBI receptor in major metabolically relevant organs. We found that GABAARγ2 increased in the liver, but not in skeletal muscle, heart or epididymal white adipose tissue (WAT) and actually decreased in interscapular brown adipose tissue (BAT) (Fig. 1D, E). Moreover, ACBP/DBI increased in liver and WAT, but remained unaltered in muscle and heart upon exposure to obesogenic diets (Fig. 1D, E). We used two additional methods to corroborate the upregulation of hepatic GABAARγ2. First, immunofluorescence staining allowed us to colocalize GABAARγ2 with the hepatocyte-specific marker albumin but not with the macrophage marker F4/80 (Fig. 2) and immunohistochemistry (Fig. 3). Of note, methionine/choline deficient diet (MCD) (which is not obesogenic, but induces hepatosteatosis and inflammation, Fig. 3B, C) also led to a diffuse, plasma membrane-localized upregulation of GABAARγ2 in the liver parenchyma (Fig. 3B, D), though a less pronounced peri-central/peri-portal upregulation than obesogenic WD (Fig. 3B, E).
Altogether, these results suggest the implication of the ACBP/DBI- GABAARγ2 system in the liver responding to obesogenic (and to some degree also non-obesogenic, steatogenic) diets.
Direct interaction between ACBP/DBI and GABAARγ2-derived eicosapeptide
Murine GABRG2 encodes a part of the heteropentameric GABAAR, and large portions of this protein subunit are surface-exposed, as determined by cryogenic electron microscopy and molecular modeling [22]. A point mutant in which the phenylalanine (F) residue in position 77 is replaced by an isoleucine (I) residue (F77I), which is surface exposed as well (Fig. 4A, B), is known to abolish the interaction of GABAAR with ACBP/DBI [13, 14]. We derived several 20-mer (eicosa) peptides in which F77 (or as a mutated control F77I) was placed in position 5, 10 or 15 and attempted to synthesize them. Only the eicosapeptides (EP) with F77 (or 77I) in position 10 were obtained at a high abundance and could be conveniently dissolved in dimethylsulfoxide (DMSO) (sequences indicated in Fig. 4C). Of note, the non-modified EP (single letter amino acid code: INMEYTIDIFFAQTWYDRRL that we refer to GABAARγ2-EP-WT) corresponds to a domain of GABRG2 that is 100% identical across different vertebrate species including zebrafish, chicken, mouse and human (Fig. S2) but specific for this GABAAR gamma chain isoform GABRB2 from human or mouse, because GABRG1 bears a ‘natural’ F77I mutation and GABRG3 bears a threonine-to-glutamine exchange in position 74 (T74Q) (Fig. S3A, B).
Molecular modeling suggested that the wild-type (WT) EP efficiently interacts with ACBP/DBI (Fig. 4B). An asparagine (N) residue in position 75 in GABAARγ2 has a high probability to form salt bridge interactions with lysine (K) residues in ACBP/DBI (either K13 or K33). Such interactions are likely to be affected by the F77I substitution found in GABAARγ1, as well as by the T74Q substitution found in GABAARγ3 (Fig. S3).
In agreement with the molecular model, GABAARγ2-EP-WT associated more rapidly with biotinylated recombinant ACBP/DBI immobilized on a surface plasmon resonance chip than did mutated GABAARγ2-EP-F77I. GABAARγ2-EP-WT also dissociated more slowly from ACBP/DBI than GABAARγ2-EP-F77I (Fig. 5A, B). Biotinylated GABAARγ2-EP-WT immobilized on streptavidin-precoated beads absorbed endogenous ACBP/DBI protein from mouse liver extracts (Fig. 5C, D), and mutated GABAARγ2-EP-F77I was less efficient in pulling down ACBP/DBI than GABAARγ2-EP-WT (Fig. 5E).
Altogether, these observations indicate that a linear peptide derived from GABAARγ2, GABAARγ2-EP-WT, efficiently interacts with native and recombinant ACBP/DBI. The question then arises whether GABAARγ2-EP-WT can functionally neutralize ACBP/DBI, thus acting as an ACBP/DBI antagonist.
Neutralization of ACBP/DBI by GABAARγ2-derived eicosapeptide
Primary mouse hepatocytes or human hepatocellular carcinoma Huh7 cells exposed to increasing concentrations of recombinant ACBP/DBI protein exhibit an increase in the capacity to reduce 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H tetrazolium (best known as WST-8) to a yellow-colored formazan dye within 4.5 h. This effect is similarly found for cells subjected to the knockout or knockdown of ACBP/DBI (Fig. 6A, B) and is abolished by the glycolysis inhibitor 2-deoxy-D-glucose (Fig. 6C) or the respiratory chain complex I inhibitor rotenone (Fig. 6D), suggesting that it reflects metabolic activation of the cells by ACBP/DBI, in accordance with the known capacity of NAD(P)H to reduce tetrazolium salts [23]. Addition of a monoclonal antibody specific for ACBP/DBI interfered with metabolic activation of Huh7 cells by ACBP/DBI (Fig. 6E). Similarly, GABAARγ2-EP-WT (but not GABRG2-EP-F77I) inhibited the ACBP/DBI-stimulated metabolic activation of Huh7 cells (Fig. 6F). We also took advantage of transgenic mice expressing microtubule-associated proteins 1A/1B light chain 3B (hereafter referred to as LC3) fused to green fluorescent protein (GFP). We obtained purified hepatocytes from such GFP-LC3-expressing transgenic mice, which were cultured in the presence of leupeptin (to block the final steps of autophagic flux) alone or in combination with the GABAARγ2-EP-WT for 16 h. We observed that the GABAARγ2-EP-WT increased the number of LC3-GFP dots observable by means of a confocal microscope (Supplementary Fig. 4). These results plead in favor of the capacity of the GABAARγ2-EP-WT to enhance autophagic flux.
In the next step, we investigated the capacity of GABAARγ2-EP-WT to interfere with the function of ACBP/DBI in vivo. For this, we first intravenously injected C57BL/6 mice with recombinant ACBP/DBI protein alone or in combination with GABAARγ2-EP-WT (or its mutated control GABAARγ2-EP-F77I) and measured food intake 30 min after administration (Fig. 7A). As previously reported [8], recombinant ACBP/DBI induced an increase in appetite. This hyperphagy effect of ACBP/DBI was abolished by GABAARγ2-EP-WT but not by its mutated counterpart GABAARγ2-EP-F77I (Fig. 7B). In the next experiment, we investigated whether GABAARγ2-EP-WT might inhibit endogenous ACBP/DBI as well. Indeed, we have previously described that antibody-mediated ACBP/DBI neutralization induces autophagy in the liver [8] and reduces the acute hepatotoxic effect of the lectin concanavalin A [9]. Moreover, we have observed that activation of autophagy in the liver was induced by the injection of GABAARγ2-EP-WT peptides (Fig. 7C, D). Preconditioning the mice with GABAARγ2-EP-WT shortly before concanavalin A injection significantly blunted the surge in plasma levels of alanine and aspartate aminotransferases (ALT and AST), two enzymes that are released from damaged and dying hepatocytes (Fig. 7E–G) [9].
In sum, these data suggest that GABAARγ2-EP-WT might act as an ACBP/DBI antagonist and hence block the effects of exogenous recombinant ACBP/DBI in vitro and in vivo, as it also interferes with the effect of endogenous (hepatotoxicity-enabling) ACBP/DBI in vivo.
Discussion
When in excess, the interaction between extracellular ACBP/DBI and the γ2 subunit of GABAAR can be highly pathogenic, contributing to cell loss, inflammation and fibrosis (as discussed in the “Introduction”) in the liver. This also applies to other organs. Thus, the ACBP/DBI neutralization protects against lung fibrosis induced by bleomycin, as well as against myocardium infarction [9] and anthracycline-induced cardiac aging [24, 25]. Moreover, ACBP/DBI knockout protects against stroke in a mouse model [26]. It is known that several of these conditions responding to ACBP/DBI neutralization are accompanied by elevations of circulating ACBP/DBI plasma levels, as documented for obesity [8, 10], non-alcoholic steatohepatitis [12] and systemic inflammation [27]. In addition, as shown here, it appears that liver damage induced by obesogenic nutrition as well as non-obesogenic (but hepatosteatosis-inducing) methionine/choline deficient diet is accompanied by the upregulation of the ACBP/DBI receptor GABAARγ2 on hepatocytes. This further supports the potential pathogenic effects of ACBP/DBI on metabolically active cells.
The appetite stimulatory and metabolic disease-inducing effects of ACBP/DBI are lost in mice bearing a point mutation (F77I) in Gabrg2 that abolishes the receptor-ligand interaction [9, 16]. This finding pleads in favor of the idea that GABAAR receptors containing this particular γ2 subunit (GABRG2 instead of GABRG1 or GABRG3) are the sole responders to extracellular ACBP/DBI. Accordingly, the F77I mutation occurs ‘naturally’ in GABRG1, contrasting with GABRG3 that encodes for an F residue in this position but has exchanged another amino acid (T74Q) only 4 positions upstream. In contrast, F77I and the stretch of amino acids flanking F77I in GABRG2 are 100% conserved across vertebrate evolution. An eicosapeptide containing 9 amino acids N-terminal from F77 and 10 amino acids C-terminal from F77 (i.e., the GABAARγ2-EP-WT peptide with the sequence INMEYTIDIFFAQTWYDRRL) was able to interact with ACBP/DBI in silico, in biophysical assays involving recombinant ACBP/DBI protein, as well as in pulldown experiments performed on liver extracts containing native ACBP/DBI. These reactivities were attenuated for a mutated eicosapeptide carrying the F77I mutation. Functional experiments confirmed that GABAARγ2-EP-WT efficiently blocked the effects of recombinant human ACBP/DBI protein on human hepatocytes, as well as the hyperphagy-stimulatory effects of mouse ACBP/DBI protein in vivo, commensurate with its capacity to attenuate acute hepatotoxicity induced by concanavalin A. Thus, GABAARγ2-EP-WT showed similar effects as antibodies specific for ACBP/DBI in thus far that it acts as an ACBP/DBI antagonist.
The aforementioned results may pave the way to the development of peptidomimetics or – more generally – small molecules blocking the interaction between ACBP/DBI and GABAARγ2 or – more specifically – the binding of ACBP/DBI to GABAARγ2-EP-WT. This latter interaction can be measured by surface plasmon resonance, greatly facilitating high-throughput screens. Such screens could be preceded by artificial intelligence-assisted preselection of molecules, the structure of which likely interferes with the binding of ACBP/DBI and GABAARγ2 in silico, as predicted by molecular modeling. That said, after more than a decade of pharmacological and clinical development, antibodies that block the – in economic terms – most lucrative protein-protein interaction between PD-1 and PD-L1 have not been replaced by small molecules (to date there has only been one successful clinical trial [28]), illustrating the difficulty to achieve the substitution of antibodies by small molecule entities. Notwithstanding this caveat, it will be important to pursue the development of synthetic, orally available ACBP/DBI antagonists for therapeutic interventions on metabolic disease.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Neess D, Bek S, Engelsby H, Gallego SF, Faergeman NJ. Long-chain acyl-CoA esters in metabolism and signaling: role of acyl-CoA binding proteins. Prog Lipid Res. 2015;59:1–25.
Du ZY, Arias T, Meng W, Chye ML. Plant acyl-CoA-binding proteins: an emerging family involved in plant development and stress responses. Prog Lipid Res. 2016;63:165–81.
Qiu S, Zeng B. Advances in understanding the Acyl-CoA-binding protein in plants, mammals, yeast, and filamentous fungi. J Fungi. 2020;6:34.
Fabrizio P, Hoon S, Shamalnasab M, Galbani A, Wei M, Giaever G, et al. Genome-wide screen in Saccharomyces cerevisiae identifies vacuolar protein sorting, autophagy, biosynthetic, and tRNA methylation genes involved in life span regulation. PLoS Genet. 2010;6:e1001024.
Xiao S, Gao W, Chen QF, Chan SW, Zheng SX, Ma J, et al. Overexpression of Arabidopsis acyl-CoA binding protein ACBP3 promotes starvation-induced and age-dependent leaf senescence. Plant Cell. 2010;22:1463–82.
Xiao S, Chye ML. The Arabidopsis thaliana ACBP3 regulates leaf senescence by modulating phospholipid metabolism and ATG8 stability. Autophagy. 2010;6:802–4.
Charmpilas N, Ruckenstuhl C, Sica V, Buttner S, Habernig L, Dichtinger S, et al. Acyl-CoA-binding protein (ACBP): a phylogenetically conserved appetite stimulator. Cell Death Dis. 2020;11:7.
Bravo-San Pedro JM, Sica V, Martins I, Pol J, Loos F, Maiuri MC, et al. Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity. Cell Metab. 2019;30:754–67.e759.
Motino O, Lambertucci F, Anagnostopoulos G, Li S, Nah J, Castoldi F, et al. ACBP/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis. Proc Natl Acad Sci USA. 2022;119:e2207344119.
Franck N, Gummesson A, Jernas M, Glad C, Svensson PA, Guillot G, et al. Identification of adipocyte genes regulated by caloric intake. J Clin Endocrinol Metab. 2011;96:E413–418.
Folli F, Guzzi V, Perego L, Coletta DK, Finzi G, Placidi C, et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients’ skin which are normalized by kidney-pancreas transplantation. PLoS ONE. 2010;5:e9923.
Arendt BM, Comelli EM, Ma DW, Lou W, Teterina A, Kim T, et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015;61:1565–78.
Dumitru I, Neitz A, Alfonso J, Monyer H. Diazepam binding inhibitor promotes stem cell expansion controlling environment-dependent neurogenesis. Neuron. 2017;94:125–37.e125.
Anagnostopoulos G, Motino O, Li S, Carbonnier V, Chen H, Sica V, et al. An obesogenic feedforward loop involving PPARgamma, acyl-CoA binding protein and GABA(A) receptor. Cell Death Dis. 2022;13:356.
Montegut L, Chen H, Bravo-San Pedro JM, Motino O, Martins I, Kroemer G. Immunization of mice with the self-peptide ACBP coupled to keyhole limpet hemocyanin. STAR Protoc. 2022;3:101095.
Joseph A, Moriceau S, Sica V, Anagnostopoulos G, Pol J, Martins I, et al. Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). Cell Death Dis. 2020;11:502.
Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004;15:1101–11.
Lambertucci F, Motino O, Perez-Lanzon M, Li S, Plantureux C, Pol J, et al. Isolation of primary mouse hepatocytes and non-parenchymal cells from a liver with precancerous lesions. Methods Mol Biol. 2024;2769:109–28.
Tsaban T, Varga JK, Avraham O, Ben-Aharon Z, Khramushin A, Schueler-Furman O. Harnessing protein folding neural networks for peptide-protein docking. Nat Commun. 2022;13:176.
Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 2023;32:e4792.
Joseph A, Chen H, Anagnostopoulos G, Montegut L, Lafarge A, Motino O, et al. Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. Cell Death Dis. 2021;12:599.
Sente A, Desai R, Naydenova K, Malinauskas T, Jounaidi Y, Miehling J, et al. Differential assembly diversifies GABA(A) receptor structures and signalling. Nature. 2022;604:190–4.
Chamchoy K, Pakotiprapha D, Pumirat P, Leartsakulpanich U, Boonyuen U. Application of WST-8 based colorimetric NAD(P)H detection for quantitative dehydrogenase assays. BMC Biochem. 2019;20:4.
Montegut L, Joseph A, Chen H, Abdellatif M, Ruckenstuhl C, Motino O, et al. High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: evidence for a phylogenetically conserved proaging function of ACBP. Aging Cell. 2023;22:e13751.
Montegut L, Abdellatif M, Motino O, Madeo F, Martins I, Quesada V, et al. Acyl coenzyme A binding protein (ACBP): An aging- and disease-relevant “autophagy checkpoint”. Aging Cell. 2023;22:e13910.
Lamtahri R, Hazime M, Gowing EK, Nagaraja RY, Maucotel J, Alasoadura M, et al. The Gliopeptide ODN, a ligand for the benzodiazepine site of GABA(A) receptors, boosts functional recovery after stroke. J Neurosci. 2021;41:7148–59.
Clavier T, Tonon MC, Foutel A, Besnier E, Lefevre-Scelles A, Morin F, et al. Increased plasma levels of endozepines, endogenous ligands of benzodiazepine receptors, during systemic inflammation: a prospective observational study. Crit Care. 2014;18:633.
Koblish HK, Wu L, Wang LS, Liu PCC, Wynn R, Rios-Doria J, et al. Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor. Cancer Discov. 2022;12:1482–99.
Acknowledgements
GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; European Research Council Advanced Investigator Grant “ICD-Cancer”, FRM; a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); European Research Council (ICD-Cancer), European Union Horizon 2020 Projects Oncobiome and Crimson (grant agreement No. 101016923); Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. UN-R is supported by Axudas de apoio á etapa de formación posdoutoral da Xunta de Galicia – GAIN. N° Expediente: IN606B-2021/015. ES is supported by the University of Las Palmas de Gran Canaria (ULPGC), financed by the Ministry of Universities (UNI/501/2021), and by the European Union-Next Generation EU Funds. The authors thank the CRC core facilities (especially CEF) for the technical and methodological help, assistance and support. Slide preparation was performed by PETRA platform and image acquisition was performed by the CRC “Histology, Imaging and Cytometry Center (CHIC)”.
Author information
Authors and Affiliations
Contributions
GA, OM, FL, and UN-R performed the in vivo experiments. ES performed most of the mammalian cell biology studies. GA and JD performed the surface plasmon resonance studies. DR-V, VQ and CL-O performed the computational modeling. HC performed the analysis of plasma ACBP/DBI concentration levels. GA, KA-V, FL, YR and AS performed the imaging analysis. LM, JD, MD-M, MC, MCM and CL-O provided intellectual input. IM and GK supervised the study. GA, IM and GK wrote the paper with input from all other authors.
Corresponding authors
Ethics declarations
Competing interests
GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. GK has been consulting for Reithera. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK, IM and OM are inventors of patent covering the therapeutic use of anti-ACBP/DBI antibodies. GK’s wife, Laurence Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. The others co-authors declare no conflict of interest.
Ethics approval
All animal experiments were conducted in accordance with the local Animal Experimental Ethics Committee (protocols ##25355-2020050715057113 v4, ##31411-2021050411267667 v3, #31018-2021041210419925 v4 and #25000-2020040718432518 v4).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by Professor Mauro Piacentini
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Anagnostopoulos, G., Saavedra, E., Lambertucci, F. et al. Inhibition of acyl-CoA binding protein (ACBP) by means of a GABAARγ2-derived peptide. Cell Death Dis 15, 249 (2024). https://doi.org/10.1038/s41419-024-06633-6
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-024-06633-6